Copyright: ©Author(s) 2026.
World J Clin Oncol. Mar 24, 2026; 17(3): 116062
Published online Mar 24, 2026. doi: 10.5306/wjco.v17.i3.116062
Published online Mar 24, 2026. doi: 10.5306/wjco.v17.i3.116062
Figure 2 Distribution of fertility-sparing treatment modalities.
LNG-IUD: Levonorgestrel-releasing intrauterine device; MA: Megestrol acetate.
- Citation: Jamil A, Sughra G, Abbasi GD, Adane S, Punshi M, Muhammad MG, Nausherwan M, Ishtiaq Y, Hazoor MD. Oncologic safety and reproductive outcomes of conservative therapy for early-stage endometrial disease. World J Clin Oncol 2026; 17(3): 116062
- URL: https://www.wjgnet.com/2218-4333/full/v17/i3/116062.htm
- DOI: https://dx.doi.org/10.5306/wjco.v17.i3.116062